Skip to main content
. 2007 Nov 12;153(2):390–401. doi: 10.1038/sj.bjp.0707568

Figure 1.

Figure 1

Characterization of cannabinoid ligands in recombinant rat CB1 and CB2 cyclase assay systems. A-796260 (a), WIN 55,212-2 (b) and CP 55,940 (c) were tested in rat CB1 and CB2 cyclase assays. Levels of receptor activation are calculated as the reduction of cAMP levels and are expressed as a percentage relative to the response of 10 μM CP 55,940. Typically, 10 μM CP 55,940 inhibits forskolin-induced cAMP levels in rat CB1 and CB2 cyclase assays by 90 and 63%, respectively; these responses were normalized to 100% activation of receptor activity. (d) The effects of A-796260, AM1241, GW-842166X and L-768,242 (GW405833) at the rat CB2 receptor.